Hims Halts Sales of Wegovy Copycat Following FDA Scrutiny
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Should l Buy HIMS?
Source: stocktwits
- Regulatory Pressure Halts Sales: Hims announced the cessation of its $49 compounded semaglutide pill following FDA scrutiny, demonstrating the company's swift response to legal threats, even as retail sentiment remains optimistic.
- FDA Action Raises Legal Risks: The FDA plans to restrict access to GLP-1 ingredients in compounded drugs and refer Hims to the Department of Justice, indicating significant compliance challenges that could impact the company's future market performance.
- Competitors Push Back: Novo Nordisk and Eli Lilly strongly criticized Hims' compounded drug as illegal, threatening legal action to protect their intellectual property, which may intensify market competition and affect Hims' brand image.
- Market Sentiment Remains Bullish: Despite Hims' stock price dropping about 30% year-to-date, retail investor sentiment on Stocktwits is still 'extremely bullish', reflecting confidence in the company's future potential and possibly attracting more investor attention in the short term.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HIMS is 42.88 USD with a low forecast of 29.00 USD and a high forecast of 85.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
2 Buy
7 Hold
3 Sell
Hold
Current: 23.480
Low
29.00
Averages
42.88
High
85.00
Current: 23.480
Low
29.00
Averages
42.88
High
85.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hims Halts Sales of Wegovy Copycat Following FDA Scrutiny
- Regulatory Pressure Halts Sales: Hims announced the cessation of its $49 compounded semaglutide pill following FDA scrutiny, demonstrating the company's swift response to legal threats, even as retail sentiment remains optimistic.
- FDA Action Raises Legal Risks: The FDA plans to restrict access to GLP-1 ingredients in compounded drugs and refer Hims to the Department of Justice, indicating significant compliance challenges that could impact the company's future market performance.
- Competitors Push Back: Novo Nordisk and Eli Lilly strongly criticized Hims' compounded drug as illegal, threatening legal action to protect their intellectual property, which may intensify market competition and affect Hims' brand image.
- Market Sentiment Remains Bullish: Despite Hims' stock price dropping about 30% year-to-date, retail investor sentiment on Stocktwits is still 'extremely bullish', reflecting confidence in the company's future potential and possibly attracting more investor attention in the short term.
See More
Dow Jones Surpasses 50,000 for the First Time
- Historic Dow Close: The Dow Jones Industrial Average closed above 50,000 for the first time, surging approximately 2.5%, which signifies a notable improvement in market sentiment and may attract more investors to the U.S. stock market.
- Asia-Pacific Market Rebound: Japan's Nikkei jumped over 4%, primarily benefiting from the ruling LDP securing a two-thirds majority in the lower house, indicating potential for looser fiscal policies that could stimulate economic growth.
- Systematic Selling Pressure: Goldman Sachs anticipates that selling pressure from systematic funds could persist following the S&P 500 breaching a short-term CTA sell trigger, estimating around $33 billion in selling this week, which may further exacerbate market volatility.
- Surge in Capital Expenditure: Alphabet, Amazon, Meta, and Microsoft plan to invest a combined $650 billion in 2026 for data centers and chips, representing a roughly 60% increase from 2025, which will drive long-term growth potential in related sectors.
See More
Worst Performing Large-Cap Stocks Last Week
- Stellantis Loss Warning: Stellantis (NYSE:STLA) plummeted 26.24% this week after the company warned of a full-year net loss, significantly eroding investor confidence and potentially impacting future financing capabilities.
- Gartner Earnings Miss: Gartner (NYSE:IT) fell 25.41% this week following the release of its fourth-quarter financial results and a downward revision of its FY26 guidance, with analysts' pessimistic outlook likely to exert further pressure on the stock.
- Reddit Stock Decline: Reddit (NYSE:RDDT) dropped 23.10% this week as multiple analysts lowered their price forecasts, reflecting market concerns over its profitability and potentially hindering its financing and expansion plans.
- Analyst Downgrades: Several analysts adjusted their price targets downward for these companies, indicating a widespread bearish sentiment regarding their future performance, which may lead investors to reassess their portfolios.
See More
Hims & Hers Halts Compounded Semaglutide Pill Offering
- Decision to Halt Sales: Hims & Hers has decided to cease offering its compounded semaglutide pill priced at $49 per month just days after its launch, reflecting the company's responsiveness to stakeholder feedback, although this may negatively impact its market share and stock price.
- FDA Warning Impact: The U.S. Food and Drug Administration (FDA) has warned it will restrict GLP-1 active pharmaceutical ingredients for non-FDA-approved compounded drugs, prompting Hims & Hers to respond to regulatory pressures that could lead to stricter compliance requirements for the company.
- Escalating Legal Threats: Novo Nordisk has issued legal threats against Hims & Hers, accusing the company of deceptive marketing practices in the sale of compounded drugs, which could result in significant financial liabilities for Hims & Hers amid ongoing litigation.
- Stock Price Volatility Risk: Following the launch of the compounded drug, Hims & Hers' stock experienced a surge; however, due to legal disputes and regulatory pressures, the stock now faces downward risks, necessitating investor vigilance regarding the company's future compliance and market strategies.
See More
Hims & Hers Abandons Wegovy Knockoff Plan Amid FDA Pressure
- Plan Abandonment: Hims & Hers announced on Saturday the abandonment of its plan to offer a knockoff version of the Wegovy weight-loss pill, prompted by the FDA's threat to restrict access to necessary ingredients, highlighting the regulatory challenges faced by innovative drug offerings.
- Market Competition: Hims had intended to sell its version at $49, significantly undercutting Novo Nordisk's $149 price, but had to retract amid legal threats, reflecting the intense competition in the obesity medication market.
- Industry Response: Hims stated that constructive conversations with industry stakeholders led to the decision to halt the treatment, indicating the company's commitment to compliance and safety, even as its website continued to promote the drug.
- Future Outlook: The FDA is expected to declare in 2024 that GLP-1 drugs are no longer in shortage, which may end the compounding practices of companies like Hims, potentially impacting their position in the rapidly growing weight-loss medication market.
See More
Hims & Hers Halts Sales of Wegovy Drug Amid FDA Pressure
- Sales Halt Decision: Hims & Hers Health has decided to cease offering the compounded version of Novo Nordisk's Wegovy (semaglutide) pill after constructive discussions with industry stakeholders, reflecting the company's commitment to compliance and sensitivity to market dynamics.
- FDA Regulatory Pressure: FDA Commissioner Marty Makary announced plans to target companies manufacturing mass-market copycat drugs, indicating a stringent regulatory stance that could impact the market performance of similar products.
- Legal Threat Context: Novo Nordisk issued a legal threat against Hims & Hers Health on February 5, highlighting its strong concern over market competition, which may lead to further legal challenges for Hims & Hers in the future.
- Market Reaction: Following the cessation of the compounded drug sales, Hims & Hers experienced negative market reactions, reflecting investor concerns regarding the company's strategic adjustments and potentially impacting its long-term value creation capabilities.
See More
Hims Halts Sales of Wegovy Copycat Following FDA Scrutiny
- Regulatory Pressure Halts Sales: Hims announced the cessation of its $49 compounded semaglutide pill following FDA scrutiny, demonstrating the company's swift response to legal threats, even as retail sentiment remains optimistic.
- FDA Action Raises Legal Risks: The FDA plans to restrict access to GLP-1 ingredients in compounded drugs and refer Hims to the Department of Justice, indicating significant compliance challenges that could impact the company's future market performance.
- Competitors Push Back: Novo Nordisk and Eli Lilly strongly criticized Hims' compounded drug as illegal, threatening legal action to protect their intellectual property, which may intensify market competition and affect Hims' brand image.
- Market Sentiment Remains Bullish: Despite Hims' stock price dropping about 30% year-to-date, retail investor sentiment on Stocktwits is still 'extremely bullish', reflecting confidence in the company's future potential and possibly attracting more investor attention in the short term.
See More
Dow Jones Surpasses 50,000 for the First Time
- Historic Dow Close: The Dow Jones Industrial Average closed above 50,000 for the first time, surging approximately 2.5%, which signifies a notable improvement in market sentiment and may attract more investors to the U.S. stock market.
- Asia-Pacific Market Rebound: Japan's Nikkei jumped over 4%, primarily benefiting from the ruling LDP securing a two-thirds majority in the lower house, indicating potential for looser fiscal policies that could stimulate economic growth.
- Systematic Selling Pressure: Goldman Sachs anticipates that selling pressure from systematic funds could persist following the S&P 500 breaching a short-term CTA sell trigger, estimating around $33 billion in selling this week, which may further exacerbate market volatility.
- Surge in Capital Expenditure: Alphabet, Amazon, Meta, and Microsoft plan to invest a combined $650 billion in 2026 for data centers and chips, representing a roughly 60% increase from 2025, which will drive long-term growth potential in related sectors.
See More
Worst Performing Large-Cap Stocks Last Week
- Stellantis Loss Warning: Stellantis (NYSE:STLA) plummeted 26.24% this week after the company warned of a full-year net loss, significantly eroding investor confidence and potentially impacting future financing capabilities.
- Gartner Earnings Miss: Gartner (NYSE:IT) fell 25.41% this week following the release of its fourth-quarter financial results and a downward revision of its FY26 guidance, with analysts' pessimistic outlook likely to exert further pressure on the stock.
- Reddit Stock Decline: Reddit (NYSE:RDDT) dropped 23.10% this week as multiple analysts lowered their price forecasts, reflecting market concerns over its profitability and potentially hindering its financing and expansion plans.
- Analyst Downgrades: Several analysts adjusted their price targets downward for these companies, indicating a widespread bearish sentiment regarding their future performance, which may lead investors to reassess their portfolios.
See More
Hims & Hers Halts Compounded Semaglutide Pill Offering
- Decision to Halt Sales: Hims & Hers has decided to cease offering its compounded semaglutide pill priced at $49 per month just days after its launch, reflecting the company's responsiveness to stakeholder feedback, although this may negatively impact its market share and stock price.
- FDA Warning Impact: The U.S. Food and Drug Administration (FDA) has warned it will restrict GLP-1 active pharmaceutical ingredients for non-FDA-approved compounded drugs, prompting Hims & Hers to respond to regulatory pressures that could lead to stricter compliance requirements for the company.
- Escalating Legal Threats: Novo Nordisk has issued legal threats against Hims & Hers, accusing the company of deceptive marketing practices in the sale of compounded drugs, which could result in significant financial liabilities for Hims & Hers amid ongoing litigation.
- Stock Price Volatility Risk: Following the launch of the compounded drug, Hims & Hers' stock experienced a surge; however, due to legal disputes and regulatory pressures, the stock now faces downward risks, necessitating investor vigilance regarding the company's future compliance and market strategies.
See More
Hims & Hers Abandons Wegovy Knockoff Plan Amid FDA Pressure
- Plan Abandonment: Hims & Hers announced on Saturday the abandonment of its plan to offer a knockoff version of the Wegovy weight-loss pill, prompted by the FDA's threat to restrict access to necessary ingredients, highlighting the regulatory challenges faced by innovative drug offerings.
- Market Competition: Hims had intended to sell its version at $49, significantly undercutting Novo Nordisk's $149 price, but had to retract amid legal threats, reflecting the intense competition in the obesity medication market.
- Industry Response: Hims stated that constructive conversations with industry stakeholders led to the decision to halt the treatment, indicating the company's commitment to compliance and safety, even as its website continued to promote the drug.
- Future Outlook: The FDA is expected to declare in 2024 that GLP-1 drugs are no longer in shortage, which may end the compounding practices of companies like Hims, potentially impacting their position in the rapidly growing weight-loss medication market.
See More
Hims & Hers Halts Sales of Wegovy Drug Amid FDA Pressure
- Sales Halt Decision: Hims & Hers Health has decided to cease offering the compounded version of Novo Nordisk's Wegovy (semaglutide) pill after constructive discussions with industry stakeholders, reflecting the company's commitment to compliance and sensitivity to market dynamics.
- FDA Regulatory Pressure: FDA Commissioner Marty Makary announced plans to target companies manufacturing mass-market copycat drugs, indicating a stringent regulatory stance that could impact the market performance of similar products.
- Legal Threat Context: Novo Nordisk issued a legal threat against Hims & Hers Health on February 5, highlighting its strong concern over market competition, which may lead to further legal challenges for Hims & Hers in the future.
- Market Reaction: Following the cessation of the compounded drug sales, Hims & Hers experienced negative market reactions, reflecting investor concerns regarding the company's strategic adjustments and potentially impacting its long-term value creation capabilities.
See More
